NIH: Frontotemporal degeneration sequencing consortium: discovery, replication and validation
The National Institute of Neurological Disorders and Stroke and the National Institute on Aging invites applications for its Frontotemporal degeneration sequencing consortium: discovery, replication and validation (UG3/UH3) funding opportunity announcement.
This supports the genetic discovery, replication and validation of disease causing mutations, risk variants and genetic modifiers which contribute to the pathophysiology, proteinopathies and clinical heterogeneity representative of the neurological syndromes that are classified under the broad spectrum of frontotemporal degeneration.
This call operates in two phases:
•the UG3 phase supports genetic variant identification studies using whole genome sequencing, genetic variant replication studies using whole genome sequencing and genome sequencing analysis that incorporates the development and use of analytical pipelines that address the clinical and pathological heterogeneity of FTD, as well as, if applicable, analytical approaches that parallel or complement pipelines currently applied to large scale genome sequencing studies being utilised in the Alzheimer’s Disease Sequencing Project and the Parkinson’s Disease Genome Sequencing Consortium;
•the UH3 phase supports additional replication studies using whole genome sequencing and functional validation studies using multi-omic approaches, human cell-based assays and in vivo studies in existing FTD model systems.
Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.
The total budget is USD 1.75 million to fund one to three awards in fiscal year 2017. Application budgets are worth up to USD 600,000 for the two-year UG3 phase; USD 750,000 for the three-year UH3 phase. The combined maximum project period is five years.
Closing date: 10th February 2017
See: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-017.html for further information